profit from every MX$100 of sales.
MX$0MX$100
Genomma Lab Internacional, S.A.B. de C.V.
MX$15.76-1.25% today
-11.1% in 1 year
1-year low MX$12.321-year high MX$19.30
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay MX$9.55 for every MX$1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Genomma Lab Internacional, S.A.B. de C.V. vs. similar companies
Genomma Lab Internacional, S.A.B. de C.V. grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from MX$100 of sales | Sales growth a year | Price per MX$1 of profit |
|---|---|---|---|
| Genomma Lab Internacional, S.A.B. de C.V. | 9.5× · Cheap | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads Genomma Lab Internacional, S.A.B. de C.V.'s last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- 9.5×
- –
- 1.68
- 1.3×
- 0.9×
- 7.6×
- –
- 13.2%
- 10.5%
- –
Profitability
- 62.8%
- 21.4%
- 9.2%
- –
- 12.1%
- 12.6%
- –
- –
- –
- –
Growth
- +1.4%
- +5.7%
- –
- –
- −0.5%
Financial health
- 1.3×
- 0.69
- –
- 4.1×
- 1.80
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 21%of 946
Top 21%of 883
Top 8%of 584
Bottom 20%of 874
Top 5%of 987
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
70Pass
Benjamin Graham
80Pass
Philip Fisher
64Pass
Peter Lynch
38No pass
Joel Greenblatt
59No pass
Charlie Munger
56No pass
Terry Smith
52No pass
Questions about Genomma Lab Internacional, S.A.B. de C.V.
Is Genomma Lab Internacional, S.A.B. de C.V. a good stock to buy?
A solid business, and the price looks low. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Genomma Lab Internacional, S.A.B. de C.V. AI analysis
What does Genomma Lab Internacional, S.A.B. de C.V. do?
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It is in Drug Manufacturers - Specialty & Generic.
Is Genomma Lab Internacional, S.A.B. de C.V. stock halal?
No. Genomma Lab Internacional, S.A.B. de C.V. does not pass our halal screen: its debt is 50% of its market value, at or above the 33% limit. How we check
How has Genomma Lab Internacional, S.A.B. de C.V. stock done over the past year?
Down 11.1% over the past twelve months, to MX$15.76. It traded between MX$12.32 and MX$19.30 and is 18.3% below its high.
Who are Genomma Lab Internacional, S.A.B. de C.V.'s competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Genomma Lab Internacional, S.A.B. de C.V.'s.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.